CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016', provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics. 

The report provides comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) 
- The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects 
- The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Overview 8
Therapeutics Development 9
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Stage of Development 9
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Therapy Area 10
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Indication 11
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Companies 15
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Products under Development by Universities/Institutes 18
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development 27
Biogen Inc 27
Bristol-Myers Squibb Company 28
eTheRNA Immunotherapies NV 29
ImmuNext, Inc. 30
Juno Therapeutics Inc. 31
MedImmune, LLC 32
Mologen AG 33
Targovax ASA 34
XL-protein GmbH 35
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles 36
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BIIB-063 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BMS-986004 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Delta-24-RGDOX - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
hepatitis B vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ISF-35 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
LOAd-700 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MEDI-4920 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
MegaCD40L - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
MGN-1601 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ONCOS-402 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
PG-10203 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
TDI-28 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
TDI-846 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
UltraCD40L - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
XL-050 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Projects 60
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Featured News & Press Releases 62
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma 62
Sep 16, 2015: MOLOGEN is presenting poster on MGN1601 at International Cancer Immunotherapy Conference 62
Sep 18, 2014: MOLOGEN Presents Poster Presentations of MGN1601 at ESMO 2014 Congress 63
May 07, 2014: MOLOGEN: Immunological data on renal cancer therapy MGN1601 presented at CIMT 63
Feb 03, 2014: MOLOGEN: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium 64
Oct 01, 2012: Mologen Presents Updated Data On Renal Cancer Therapy MGN1601 At European Society For Medical Oncology 2012 65
Mar 30, 2012: MOLOGEN Announces Treatment With Renal Cancer Therapy MGN1601 Generates Clear Survival Benefit For Patients 65
Feb 21, 2012: MOLOGEN Wins Patent Protection In Japan For Cell-Based Cancer Therapy MGN1601 67
Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting 67
Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule 68
Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule 69
Aug 29, 2011: MOLOGEN Publishes First Results From Phase I/II Clinical Trial With Cell-Based Renal Cancer Therapy MGN1601 70
Aug 29, 2011: MOLOGEN Publishes Results From Phase I/II Clinical Trial Of Renal Cancer Therapy 71
Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 71
Feb 23, 2011: MOLOGEN To Receive Europen Patent For Allogenic Tumor Therapy 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Biogen Inc, H2 2016 27
Pipeline by Bristol-Myers Squibb Company, H2 2016 28
Pipeline by eTheRNA Immunotherapies NV, H2 2016 29
Pipeline by ImmuNext, Inc., H2 2016 30
Pipeline by Juno Therapeutics Inc., H2 2016 31
Pipeline by MedImmune, LLC, H2 2016 32
Pipeline by Mologen AG, H2 2016 33
Pipeline by Targovax ASA, H2 2016 34
Pipeline by XL-protein GmbH, H2 2016 35
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61